- Home
- LXRX
as 07-26-2024 4:00pm EST
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
Upcoming Earnings Alert:
Get ready for potential market movements as Lexicon Pharmaceuticals Inc. LXRX prepares to release earnings report on 01 Aug 2024.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | THE WOODLANDS |
| Market Cap: | 605.5M | IPO Year: | 2000 |
| Target Price: | $10.00 | AVG Volume (30 days): | 3.2M |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.92 - $3.73 | Next Earning Date: | 08-01-2024 |
| Revenue: | $2,311,000 | Revenue Growth: | 1734.13% |
| Revenue Growth (this year): | 1942.86% | Revenue Growth (next year): | 247.08% |
Stock Insider Trading Activity of Lexicon Pharmaceuticals Inc. (LXRX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| COATS LONNEL | LXRX | Chief Executive Officer | Nov 16 '23 | Buy | $1.05 | 90,000 | $94,797.00 | 914,359 | SEC Form 4 |
Latest Lexicon Pharmaceuticals Inc. News
LXRX Breaking Stock News: Dive into LXRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024
Zacks
8 days ago
Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
Zacks
9 days ago
FDA Accepts Lexicon's (LXRX) NDA for Type I Diabetes Drug
MT Newswires
10 days ago
Update: FDA Sets Target Action Date for Lexicon Pharmaceuticals' NDA Resubmission for Sotagliflozin
MT Newswires
10 days ago
FDA Sets PDUFA Goal Date for Lexicon Pharmaceuticals' NDA Resubmission for Sotagliflozin
GlobeNewswire
10 days ago
Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission
GlobeNewswire
11 days ago
New Published Data Highlights Potential Cost-Savings of INPEFA® (sotagliflozin) for Heart Failure
Simply Wall St.
16 days ago
Private equity firms account for 48% of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) ownership, while individual investors account for 33%
Compare LXRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LXRX Lexicon Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.